Recent FDA Approved Drug Offers Hope for New Lease on Life for Many Cancer Patients
Cancer-free Stem Cell Transplant Patient - Among First in World Treated with New Therapy - and Medical Expert on New Innovative Biotechnology Treatment
The U.S. Food and Drug Administration has granted marketing approval for Mozobil, a drug intended to help mobilize stem cells to the bloodstream for collection and subsequent transplantation in patients with non-Hodgkins lymphoma (NHL) and multiple myeloma (MM).
This is an important advancement in the treatment of patients with certain types of cancer who require a stem cell transplant using their own stem cells. In order for a transplant to take place, a minimum number of stem cells must be collected from the patient's bone marrow, a process that can take three or four hours over multiple days to complete. Even then, many patients are not able to mobilize enough stem cells, and a transplant is not possible. For many cancer patients, a stem cell transplant is their only hope for remission or a cure.
Patients who received Mozobil in conjunction with a growth factor were more likely to mobilize a sufficient number of stem cells compared to patients treated with growth factor alone.
NHL is the sixth most common cancer in the U.S. among males and the fifth most common cancer among females. More than 66,000 new cases were reported in 2008, with 19,000 deaths. The cancer starts in the white blood cells that are part of the lymphatic system. MM is a cancer that begins in plasma cells, it is also the most common type of plasma cell tumor, with almost 20,000 new cases reported and nearly 11,000 deaths projected for 2008.
Talent/Guest: Dr. John F. DiPersio, M.D., Ph.D. Washington University School of Medicine
Dr. DiPersio is the Chief of the Division of Oncology at the Washington University School of Medicine in St. Louis. He is one of the world's leading specialists on stem cell transplantation, and his research has been featured in a number of leading medical journals.
Talent/Guest: Paul Barrath, Diagnosed with non-Hodgkin's Lymphoma
Paul is 59 and is the vice president of a design and building firm for finance institutions. He is married with two children. He was diagnosed with non-Hodgkin's lymphoma in November 2005. Following treatment with two rounds of intensive chemotherapy, his cancer went into remission. By May of 2006 the cancer had returned, and his oncologist told him that he needed a stem cell transplant. Two attempts to collect enough stem cells failed. Following treatment with Mozobil, the collection process was successful and Paul was able to advance to a transplant. He has been cancer-free for more than two years. Without the transplant, Paul's only option was to have a blood transfusion every two weeks for life.
Source: Genzyme Corporation
Arizona Internet Marketing
Arizona Biotechnology Marketing
Biotechnology News
The U.S. Food and Drug Administration has granted marketing approval for Mozobil, a drug intended to help mobilize stem cells to the bloodstream for collection and subsequent transplantation in patients with non-Hodgkins lymphoma (NHL) and multiple myeloma (MM).
This is an important advancement in the treatment of patients with certain types of cancer who require a stem cell transplant using their own stem cells. In order for a transplant to take place, a minimum number of stem cells must be collected from the patient's bone marrow, a process that can take three or four hours over multiple days to complete. Even then, many patients are not able to mobilize enough stem cells, and a transplant is not possible. For many cancer patients, a stem cell transplant is their only hope for remission or a cure.
Patients who received Mozobil in conjunction with a growth factor were more likely to mobilize a sufficient number of stem cells compared to patients treated with growth factor alone.
NHL is the sixth most common cancer in the U.S. among males and the fifth most common cancer among females. More than 66,000 new cases were reported in 2008, with 19,000 deaths. The cancer starts in the white blood cells that are part of the lymphatic system. MM is a cancer that begins in plasma cells, it is also the most common type of plasma cell tumor, with almost 20,000 new cases reported and nearly 11,000 deaths projected for 2008.
Talent/Guest: Dr. John F. DiPersio, M.D., Ph.D. Washington University School of Medicine
Dr. DiPersio is the Chief of the Division of Oncology at the Washington University School of Medicine in St. Louis. He is one of the world's leading specialists on stem cell transplantation, and his research has been featured in a number of leading medical journals.
Talent/Guest: Paul Barrath, Diagnosed with non-Hodgkin's Lymphoma
Paul is 59 and is the vice president of a design and building firm for finance institutions. He is married with two children. He was diagnosed with non-Hodgkin's lymphoma in November 2005. Following treatment with two rounds of intensive chemotherapy, his cancer went into remission. By May of 2006 the cancer had returned, and his oncologist told him that he needed a stem cell transplant. Two attempts to collect enough stem cells failed. Following treatment with Mozobil, the collection process was successful and Paul was able to advance to a transplant. He has been cancer-free for more than two years. Without the transplant, Paul's only option was to have a blood transfusion every two weeks for life.
Source: Genzyme Corporation
Arizona Internet Marketing
Arizona Biotechnology Marketing
Biotechnology News
posted by Bill Austin - Recent FDA Approved Drug Offers Hope for New Lease on Life for Many Cancer Patients
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home